Is NGNE or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Rapport Therapeutics N/A -24.78% -23.44%

Is NGNE or CAPR more profitable?

Neurogene's return on equity of -37.88% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Capricor Therapeutics N/A -59.27% -48.65%

Neurogene (NGNE) Competitors

$27.52 +1.30 (+4.94%)

As of 03:36 PM Eastern

Compare

NGNE vs. ANIP, RAPP, AGIO, SNDX, and CAPR

Should you buy Neurogene stock or one of its competitors? MarketBeat compares Neurogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurogene include ANI Pharmaceuticals (ANIP), Rapport Therapeutics (RAPP), Agios Pharmaceuticals (AGIO), Syndax Pharmaceuticals (SNDX), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical products" industry.

How does Neurogene compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 9.98% compared to Neurogene's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Neurogene	N/A	-37.88%	-34.70%

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 1 mentions for ANI Pharmaceuticals and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat ANI Pharmaceuticals' score of 1.14 indicating that Neurogene is being referred to more favorably in the news media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Neurogene	Very Positive

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

ANI Pharmaceuticals presently has a consensus target price of $107.33, indicating a potential upside of 36.41%. Neurogene has a consensus target price of $73.13, indicating a potential upside of 165.90%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

ANI Pharmaceuticals has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.03	$78.34M	$3.95	19.92
Neurogene	$930K	467.22	-$90.35M	-$4.55	N/A

Summary

ANI Pharmaceuticals beats Neurogene on 9 of the 17 factors compared between the two stocks.

How does Neurogene compare to Rapport Therapeutics?

Neurogene (NASDAQ:NGNE) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Neurogene presently has a consensus price target of $73.13, suggesting a potential upside of 165.90%. Rapport Therapeutics has a consensus price target of $58.83, suggesting a potential upside of 56.86%. Given Neurogene's higher probable upside, equities research analysts clearly believe Neurogene is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Neurogene has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	467.22	-$90.35M	-$4.55	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

In the previous week, Rapport Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Rapport Therapeutics and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Rapport Therapeutics' score of 0.58 indicating that Neurogene is being referred to more favorably in the media.

Company	Overall Sentiment
Neurogene	Very Positive
Rapport Therapeutics	Positive

Rapport Therapeutics' return on equity of -24.78% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Neurogene has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neurogene and Rapport Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Neurogene compare to Agios Pharmaceuticals?

Neurogene (NASDAQ:NGNE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Neurogene presently has a consensus target price of $73.13, suggesting a potential upside of 165.90%. Agios Pharmaceuticals has a consensus target price of $41.44, suggesting a potential upside of 42.00%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Agios Pharmaceuticals had 21 more articles in the media than Neurogene. MarketBeat recorded 21 mentions for Agios Pharmaceuticals and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Agios Pharmaceuticals' score of 0.37 indicating that Neurogene is being referred to more favorably in the media.

Company	Overall Sentiment
Neurogene	Very Positive
Agios Pharmaceuticals	Neutral

Neurogene has higher earnings, but lower revenue than Agios Pharmaceuticals. Neurogene is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	467.22	-$90.35M	-$4.55	N/A
Agios Pharmaceuticals	$54.03M	32.12	-$412.78M	-$7.25	N/A

Neurogene has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Neurogene has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Neurogene beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Neurogene compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

52.4% of Neurogene shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Syndax Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Syndax Pharmaceuticals presently has a consensus price target of $42.55, suggesting a potential upside of 138.22%. Neurogene has a consensus price target of $73.13, suggesting a potential upside of 165.90%. Given Neurogene's higher probable upside, analysts plainly believe Neurogene is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Syndax Pharmaceuticals had 7 more articles in the media than Neurogene. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Syndax Pharmaceuticals' score of 0.12 indicating that Neurogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Syndax Pharmaceuticals	Neutral
Neurogene	Very Positive

Neurogene has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Neurogene's return on equity of -37.88% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Neurogene	N/A	-37.88%	-34.70%

Neurogene has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.18	-$285.42M	-$2.79	N/A
Neurogene	$930K	467.22	-$90.35M	-$4.55	N/A

Summary

Neurogene beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Neurogene compare to Capricor Therapeutics?

Neurogene (NASDAQ:NGNE) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

In the previous week, Capricor Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Capricor Therapeutics and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Capricor Therapeutics' score of 0.12 indicating that Neurogene is being referred to more favorably in the media.

Company	Overall Sentiment
Neurogene	Very Positive
Capricor Therapeutics	Neutral

Neurogene presently has a consensus target price of $73.13, indicating a potential upside of 165.90%. Capricor Therapeutics has a consensus target price of $48.36, indicating a potential upside of 71.29%. Given Neurogene's stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Neurogene's return on equity of -37.88% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neurogene has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	467.22	-$90.35M	-$4.55	N/A
Capricor Therapeutics	$22.27M	73.42	-$105.04M	-$2.32	N/A

Summary

Neurogene beats Capricor Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$436.25M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-6.07	18.86	23.86	24.42
Price / Sales	467.22	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	1.61	6.81	10.04	6.74
Net Income	-$90.35M	$24.09M	$3.56B	$337.03M
7 Day Performance	0.00%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	26.91%	48.97%	28.80%	34.36%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	2.7573 of 5 stars	$27.52 +4.9%	$73.13 +165.8%	+27.5%	$434.75M	$930K	N/A	90	Analyst Forecast
ANIP ANI Pharmaceuticals	3.7688 of 5 stars	$76.71 -2.3%	$107.33 +39.9%	+22.0%	$1.79B	$883.37M	19.42	600	Positive News Analyst Forecast
RAPP Rapport Therapeutics	3.3422 of 5 stars	$37.11 -6.1%	$58.83 +58.5%	+202.3%	$1.77B	$20M	N/A	N/A	Analyst Forecast
AGIO Agios Pharmaceuticals	2.7734 of 5 stars	$28.00 -4.8%	$41.44 +48.0%	-17.1%	$1.75B	$54.03M	N/A	390	Trending News Analyst Revision
SNDX Syndax Pharmaceuticals	2.6273 of 5 stars	$18.85 -3.8%	$42.55 +125.7%	+63.9%	$1.74B	$217.17M	N/A	110	News Coverage Analyst Forecast Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. ANIP, RAPP, AGIO, SNDX, and CAPR

How does Neurogene compare to ANI Pharmaceuticals?

Summary

How does Neurogene compare to Rapport Therapeutics?

Summary

How does Neurogene compare to Agios Pharmaceuticals?

Summary

How does Neurogene compare to Syndax Pharmaceuticals?

Summary

How does Neurogene compare to Capricor Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. ANIP, RAPP, AGIO, SNDX, and CAPR

How does Neurogene compare to ANI Pharmaceuticals?

Do institutionals and insiders have more ownership in ANIP or NGNE?

Is ANIP or NGNE more profitable?

Does the media favor ANIP or NGNE?

Which has more volatility & risk, ANIP or NGNE?

Do analysts prefer ANIP or NGNE?

Which has stronger valuation & earnings, ANIP or NGNE?

Summary

How does Neurogene compare to Rapport Therapeutics?

Do analysts rate NGNE or RAPP?

Which has higher valuation and earnings, NGNE or RAPP?

Does the media prefer NGNE or RAPP?

Is NGNE or RAPP more profitable?

Which has more risk and volatility, NGNE or RAPP?

Do insiders and institutionals hold more shares of NGNE or RAPP?

Summary

How does Neurogene compare to Agios Pharmaceuticals?

Do analysts rate NGNE or AGIO?

Does the media refer more to NGNE or AGIO?

Which has stronger valuation and earnings, NGNE or AGIO?

Is NGNE or AGIO more profitable?

Which has more risk and volatility, NGNE or AGIO?

Do insiders and institutionals believe in NGNE or AGIO?

Summary

How does Neurogene compare to Syndax Pharmaceuticals?

Do institutionals & insiders hold more shares of SNDX or NGNE?

Which has more risk and volatility, SNDX or NGNE?

Do analysts rate SNDX or NGNE?

Does the media favor SNDX or NGNE?

Is SNDX or NGNE more profitable?

Which has better earnings and valuation, SNDX or NGNE?

Summary

How does Neurogene compare to Capricor Therapeutics?

Does the media favor NGNE or CAPR?

Do analysts recommend NGNE or CAPR?

Is NGNE or CAPR more profitable?

Which has more risk and volatility, NGNE or CAPR?

Do institutionals & insiders have more ownership in NGNE or CAPR?

Which has stronger valuation and earnings, NGNE or CAPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools